Keyword Search

Date Title
05/30/26 Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
05/28/26 Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
05/21/26 Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
05/20/26 Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
05/15/26 Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
05/13/26 Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
05/07/26 Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
04/19/26 Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
04/16/26 Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
04/10/26 Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
03/17/26 Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
03/12/26 Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
02/26/26 Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
02/18/26 Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
01/08/26 Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016